Background: This study examined potential associations between daily glucosamine (GlcN) use and the gut microbiota. Methods: In a cross-sectional sample of 200 Japanese adults aged 50–59 (100 regular GlcN users; 100 age- and sex-matched non-users), fecal 16S rRNA profiles were analyzed. α-diversity (richness, Shannon index) and β-diversity were compared; predominant genera (>1% mean abundance) were evaluated, and differential abundance was tested using ANCOM and LEfSe. A subgroup analysis assessed normal-BMI participants (18.5–25.0). Results: Overall α-diversity and β-diversity did not differ between users and non-users. Of the >150 genera detected, 22 exceeded 1% mean abundance, and their profiles were virtually identical across groups; neither ANCOM nor LEfSe identified taxa with significant differential abundance. In the normal-BMI subgroup, GlcN users showed lower species richness and a reduced prevalence of rare taxa (<10,000 total reads), with a decrease in Christensenella, which is consistent with prior intervention studies. Given reports linking Christensenella to lower frailty in specific contexts, these findings suggest a potential GlcN-related effect relevant to joint health. Conclusions: Habitual GlcN use was not strongly associated with broad changes in gut microbial diversity or common taxa in middle-aged adults, although it might have some effect on minor taxa. Longitudinal, controlled studies are warranted to confirm these findings and clarify mechanisms.
No takes yet. Share an insight, caveat, or question.
Tomoya Shintani (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: